Advancing a new generation of treatments for
central nervous system disorders
Latest News
16 Apr 2012
NeurOp Names Robert Zaczek as Chief Scientific Officer
Read More
11 Apr 2012
NeurOp Awarded $700,000 Grant for Schizophrenia Drug Research
Read More
26 Jan 2012
NeurOp Awarded Deal of the Year for Ischemia Program Funding
Read More
NeurOp, Inc. is a biopharmaceutical company developing new medicines to treat central nervous system disorders,
including major depression, neuropathic pain and ischemia. Our mission is to develop a new generation of
N-methyl-D-aspartate (NMDA) receptor blockers, which inhibit proteins that play an important role in neuron signaling.
Our compounds specifically target the NR2B subtype of these receptors offering an unprecedented
opportunity to improve the safety and tolerability of this therapeutic class without compromising efficacy.
Learn more about our science.